Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial - Fosså, Alexander; Molin, Daniel; Bröckelmann, Paul J.; Schneider, Gundolf; Schnetzke, Ulf; Linderoth, Johan; Kamper, Peter M. H.; Leppä, Sirpa M.; Meißner, Julia; Schaub, Valdete; Lia, Kjersti; Fuchs, Michael; et al. (HemaSphere, 2025)
Gesehen am 25.02.2026